Biotech Values

[mcbio]

Pharmasset looked at the drug-drug interactions with Telaprevir in vitro and concluded that antagonistic interaction is unlikely in clinical studies given the duplicity of enzymatic pathways available for delivery of the triphosphate intracellularly.

I would tend to think VRUS has likely done DDI studies with the drugs they have signed trial collaboration agreements with (TMC435 and the BMY NS5A). Given all the value built into the VRUS nukes up to that point, you wouldn't think they would agree to do combo trials with another HCV candidate that they hadn't thoroughly vetted given the risk of potential SAEs in the combo trial. It would be difficult to determine which drug would be at fault should any SAEs arise from the clinical testing of the combo so one would think VRUS would want to have a lot of confidence in any drug they are combining with 7977. Of course, DDI studies don't always translate over to the clinic.